Danaher Guides Q3 Ex-Respiratory Growth Around Five Percent — Q4 Exits Mid-Single Digit

Danaher: What’s driving the expected Q3 core-growth acceleration (ex-respiratory to ~5%) and the mid-single-digit Q4 exit?

1) The main mechanical driver: respiratory revenue headwind variability (basis points), not a change in the underlying non-respiratory trend

Danaher frames the sequential step-up largely as an accounting/mechanical effect of respiratory revenue headwinds worsening in Q3 and then easing out in Q4 on a year-over-year basis. In the call, management states that respiratory was ~150 bps headwind in Q2 and is expected to be ~250 bps headwind in Q3, and that these headwinds “essentially go away” year-on-year in Q4, which supports confidence in a Q4 mid-single-digit core growth rate. ¹

They further quantify the decomposition:

• Ex-respiratory core growth was 4.5% in Q2 (an acceleration vs Q1). ¹
• Q3 guidance assumes slight improvement off Q2 to ~5% ex-respiratory, with the biggest swing factor being respiratory revenue (i.e., the headwind magnitude changes the reported core growth). ¹
• Ex-respiratory growth in Q3 is therefore implied to be ~5%, while the reported results in Q3 are pressured by the larger respiratory headwind. ²

Implication: The “acceleration” to ~5% ex-respiratory in Q3 is not primarily attributed to respiratory improving; rather, it reflects that non-respiratory trends are steady-to-improving, while respiratory headwinds are temporarily more negative in Q3 and then normalize for Q4. ¹²

2) The underlying non-respiratory execution supports the ex-respiratory step-up

Management connects the expected improvement in ex-respiratory growth to execution and product/menu expansion across Diagnostics and Diagnostics-adjacent non-respiratory testing.

In Diagnostics, they cite new product innovations and menu expansion (e.g., Beckman’s DxI 9000 and Cepheid menu expansion) as supporting accelerated growth once you look past respiratory volatility. ³ In addition, they report that excluding respiratory, Diagnostics core revenue grew mid-single digits in Q2 and that the company expects underlying trends to continue. ³

They also provide additional support from the segment trend itself:

• They expect Q3 revenue growth of ~2%–3%, including an approximately 250 bps YoY headwind from respiratory testing, which implies core growth excluding respiratory of ~5% and “an acceleration versus” Q2. ²

So, the expected ex-respiratory ~5% in Q3 is supported by management’s view that non-respiratory Diagnostics momentum continues (execution + innovation + menu expansion) even while respiratory temporarily weighs on the reported number. ³²

3) China policy headwinds are easing—explicitly cited as a factor behind the Q3/Q4 step-up

Beyond respiratory, management explicitly calls out China policy as another contributor to the sequential improvement pattern.

In response to what drives acceleration (despite the respiratory assumption), management states:

• There is variability in respiratory headwinds quarter to quarter, but as respiratory headwinds moderate in Q4, they expect exit at mid-single digit. ³
• “Remember here… we do have China policy, those headwinds are starting to lessen.” ³
• They observe “a little bit lower of a headwind here in Q3 and Q4,” which “driv[es] a bit more of the overall step up as well.” ³

Implication: The Q3-to-Q4 improvement is described as coming from (a) respiratory headwind magnitude changing, and (b) China policy headwinds easing at the same time, which together make the exit rate assumption more credible. ³

4) Putting the two effects together: why Q3 can show ex-respiratory improvement while respiratory gets worse, and why Q4 exits at mid-single digits

Management’s logic can be summarized mechanically:

1. Q2 baseline: Ex-respiratory core growth already reached 4.5% in Q2. ¹
2. Q3 setup: For Q3, management expects slight improvement ex-respiratory to ~5%, while simultaneously expecting respiratory to be a bigger headwind in Q3 (~250 bps vs ~150 bps in Q2)—so the respiratory impact mainly affects the reported core growth, not the ex-respiratory trend quality. ¹²
3. Q4 normalization: For Q4, respiratory headwinds “go away” YoY, and China policy headwinds are described as lessening, enabling Danaher to exit Q4 at a mid-single digit core growth rate. ¹³

This is consistent with their Diagnostics-specific framing that respiratory headwind is explicitly modeled as ~250 bps YoY in Q3 and that management expects to exit Q4 past “some of the headwinds from the first three quarters of the year.” ²

5) Direct answer to the “particularly” items in your question

A) “Respiratory headwinds variability”

The expected acceleration and exit path are tied to the modeled respiratory swing:

• Respiratory headwind ~150 bps in Q2
• Respiratory headwind ~250 bps in Q3
• Headwinds essentially go away year-on-year in Q4 ¹ And management emphasizes that the biggest swing factor for quarter-to-quarter movement is respiratory revenue. ¹

B) “Easing of China policy headwinds”

Management explicitly attributes additional step-up support to the China policy effect:

• China policy headwinds are starting to lessen
• There is “a little bit lower” headwind in Q3 and Q4, contributing to the overall step up. ³

Bottom line

Danaher expects the ex-respiratory core growth rate to step up to ~5% in Q3 because non-respiratory momentum and innovation/execution continue, while the reported core growth number is buffered/pressured by a larger respiratory revenue headwind in Q3. ¹³² The company expects to exit Q4 at a mid-single-digit rate because respiratory headwinds normalize YoY (go away) in Q4, and China policy headwinds are easing into Q3/Q4, both of which management says contribute to the step-up. ¹³